- Trials with a EudraCT protocol (356)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
356 result(s) found for: Agonists.
Displaying page 5 of 18.
EudraCT Number: 2005-001725-28 | Sponsor Protocol Number: 767905/014 | Start Date*: 2005-08-26 |
Sponsor Name:GlaxoSmithKline R & D Limited | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dys... | ||
Medical condition: Opioid-induced bowel dysfunction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) FI (Completed) SE (Completed) GB (Completed) HU (Completed) AT (Completed) DK (Completed) PT (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-001724-37 | Sponsor Protocol Number: 767905/013 | Start Date*: 2005-09-08 |
Sponsor Name:GlaxoSmithKline R & D Limited | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of O... | ||
Medical condition: Opioid-induced bowel dysfunction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) HU (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000718-37 | Sponsor Protocol Number: RA/PR/033001/005/04 | Start Date*: 2004-07-30 | |||||||||||
Sponsor Name:Chiesi Farmaceutici S.p.A. | |||||||||||||
Full Title: Double blind, double dummy, multinational, multicenter, parallel-group design clinical trial of superiority of CHF 1535 1 puff in a b.i.d regimen administered via an HFA-propellant-pMDI versus a do... | |||||||||||||
Medical condition: Mild to moderate adult asthmatic patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004642-32 | Sponsor Protocol Number: 2007ENT03 | Start Date*: 2008-10-10 | |||||||||||
Sponsor Name:University of East Anglia | |||||||||||||
Full Title: THE EFFECT OF THEOPHYLLINE IN PATIENTS WITH RHINITIS | |||||||||||||
Medical condition: Rhinitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003745-32 | Sponsor Protocol Number: 7061 | Start Date*: 2008-12-12 | ||||||||||||||||
Sponsor Name:University of Nottingham | ||||||||||||||||||
Full Title: A randomised, double blind, placebo controlled trial of doxycycline in lymphangioleiomyomatosis. | ||||||||||||||||||
Medical condition: Lymphangioleiomyomatosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-004833-70 | Sponsor Protocol Number: BUSAL-III-08-1 | Start Date*: 2009-01-16 | |||||||||||
Sponsor Name:Laboratoires SMB S.A. | |||||||||||||
Full Title: A phase III, randomized, parallel group, open study to compare the therapeutic efficacy and safety of SMB BUDESONIDE-SALMETEROL DPI capsule 150/25μg BID delivered by the AXAHALER® versus SYMBICORT®... | |||||||||||||
Medical condition: Patients with moderate to severe persistent asthma. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023987-41 | Sponsor Protocol Number: 2010.2611 | Start Date*: 2011-06-24 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: In vivo imaging of the effect of fulvestrant on availability of estrogen receptor binding sites in metastatic breast tumor lesions using [18F]FES-PET | ||
Medical condition: Estrogen Receptor-positive metastatic breast cancer patients that will be treated with fulvestrant | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-005182-20 | Sponsor Protocol Number: S308.3.002 | Start Date*: 2007-02-13 | |||||||||||
Sponsor Name:Solvay Pharmaceuticals | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel group study of SLV308 as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations. | |||||||||||||
Medical condition: Advanced stage Parkinson's disease with motor fluctuations. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) LV (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016738-28 | Sponsor Protocol Number: ALISEI | Start Date*: 2009-12-11 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA PISANA | |||||||||||||
Full Title: Phase IV prospective, randomized, open with blind endpoints, parallel group study to evaluate the effect of Aliskiren on endothelial dysfunction in patients with essential hypertension | |||||||||||||
Medical condition: essential hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001523-31 | Sponsor Protocol Number: U1111-1181-4107 | Start Date*: 2017-01-30 | |||||||||||
Sponsor Name:Steno Diabetes Center Copenhagen | |||||||||||||
Full Title: Effect of liraglutide on vascular inflammation in type-2 diabetes: A randomized, placebo-controlled, double-blind, parallel clinical PET/CT trial | |||||||||||||
Medical condition: Type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017872-26 | Sponsor Protocol Number: 1147/09 | Start Date*: 2010-02-22 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Role and pharmacological modulation of lug inflammation in chronic obstructive pulmonary disease (COPD) | |||||||||||||
Medical condition: chronic obstructive pulmonary disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000478-42 | Sponsor Protocol Number: 008285QM | Start Date*: 2013-02-18 |
Sponsor Name:Queen Mary, University of London | ||
Full Title: NEPTUNE: A Randomised Phase II Study of Neoadjuvant TAK-700 and Leuprorelin Acetate versus Surgery Alone in Intermediate and High Risk Clinically Localized Prostate Cancer | ||
Medical condition: High or Intermediate Risk, Untreated, Clinically Localised Prostate Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-013791-49 | Sponsor Protocol Number: RHM MED 0879 | Start Date*: 2009-09-23 | |||||||||||
Sponsor Name:Southampton Universities Hospital Trust | |||||||||||||
Full Title: Safety and Efficacy of parenteral KGF in moderate asthma subjects | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004541-15 | Sponsor Protocol Number: FRA.LOS.2007 | Start Date*: Information not available in EudraCT |
Sponsor Name:Johann Wolfgang Goethe-Universität Frankfurt am Main | ||
Full Title: A Randomized Controlled Open-Label Phase IV Mono Center Study to Compare the Reponse Profiles of Montelukast versus Fluticason in Children with Preschool Asthma | ||
Medical condition: bronchial asthma is a very common medical problem in 3-7 year old children, often requiring hospitalization and demanding treatment on demand or permanently. Our trial is to compare to established ... | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005116-28 | Sponsor Protocol Number: 38495 | Start Date*: 2012-09-10 |
Sponsor Name: | ||
Full Title: A phase I/II trial of Cabazitaxel +/- Rhenium-188 HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment. The ReCab trial | ||
Medical condition: Metastatic prostate cancer/bone metastases | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-001587-70 | Sponsor Protocol Number: 07/03 Inopec ITEM | Start Date*: 2007-06-07 |
Sponsor Name:Fraunhofer Gesellschaft | ||
Full Title: A randomized, double-blind, placebo-controlled crossover study to assess the efficacy's reproducibility of a combination of Pseudoephedrine and Cetirizine on symptom scores and rhinomanometry in pa... | ||
Medical condition: subjects with seasonal allergic rhinitis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000164-42 | Sponsor Protocol Number: 2016RC01 | Start Date*: 2016-08-17 | |||||||||||
Sponsor Name:Tayside Medical Sciences Centre on behalf of University of Dundee | |||||||||||||
Full Title: JAB02 Repurposing allopurinol as a novel anti-inflammatory treatment for persistent allergic asthma. | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001166-13 | Sponsor Protocol Number: COU-AA-001 | Start Date*: 2005-09-21 | |||||||||||
Sponsor Name:Cougar Biotechnology, Inc | |||||||||||||
Full Title: A Phase I/II Open Label Study of the 17α-hydroxylase/ C17,20 lyase inhibitor, Abiraterone acetate, in Patients with Prostate Cancer who have failed hormone therapy | |||||||||||||
Medical condition: Hormone refractory prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020407-73 | Sponsor Protocol Number: D9830C00008 | Start Date*: 2010-10-27 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A double-blind, placebo-controlled, randomised, parallel-group, phase-II, multi-centre study to assess the efficacy, safety and tolerability of 4 twice daily doses and 2 once daily doses of AZD1981... | ||
Medical condition: asthma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000215-22 | Sponsor Protocol Number: HH3104994 | Start Date*: 2006-02-08 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: A randomised, double blind, placebo controlled, two-way crossover, three phase, study, to investigate the trial models, Vienna Challenge Chamber, in and out of season, and Park Study in season and ... | ||
Medical condition: Seasonal Allergic Rhinitis (SAR) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
